Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
The trial also demonstrated significant improvements across multiple secondary endpoints
Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation
The collaboration promises expanded funding for Thai universities, research institutes, companies, and global research partners working in Thailand
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
Analysis of over 93 lakh preventive health checkups reveals disease risks emerging as early as the 20s
Health of the Nation 2026, based on over 3 million assessments, finds rising diabetes, obesity, and hidden cardiac risks in under-30s and working professionals
Subscribe To Our Newsletter & Stay Updated
